Is MariMed A Safe Haven In The Wake Of Florida’s Cannabis Legalization Defeat?
Cannabis company MariMed Inc. (NASDAQ:MRMD) released its Q3 2024 results on November 6, announcing revised guidance for the fiscal year. While the company expects an 18–20% decline in EBITDA – down from its prior projection of flat to 2% growth – it raised its sales guidance to a 6–8% increase, up from 5–7%. These adjustments align closely with earlier projections from Zuanic & Associates, a cannabis industry research firm.
- Get Benzinga’s exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter here. You can’t afford to miss out if you’re serious about the business.
Guidance Adjustments Reflect Sector Trends
Zuanic & Associates’ October 16 report on MariMed highlighted its strategic focus on core markets, particularly in Illinois, where Zuanic’s team recently visited the company’s retail and cultivation facilities. Despite the downward revision to EBITDA, MariMed’s raised sales expectations are noteworthy given broader sector headwinds.
Cannabis stocks with exposure to Florida, for …